重大公告
Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA
1.Date of occurrence of the event:2024/02/29 2.New drug name or code:OBI-858 Novel Botulinum Neurotoxin 3.Indication: OBI-858, an in-house developed novel botulinum neurotoxin (BoNT) product, is …
Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial
1.Date of occurrence of the event:2024/01/31 2.New drug name or code: The active cancer immunotherapy Adagloxad Simolenin (OBI-822)/OBI-821 3.Indication: Adagloxad Simolenin (OBI-822) is a therapeutic …
OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial
1.Date of occurrence of the event:2024/01/03 2.New drug name or code: OBI-992 TROP2 ADC 3.Indication: OBI-992 is an antibody drug conjugate (ADC) for cancer treatment …
Announcement on behalf of Amaran that its institutional director changes its representative
1.Date of occurrence of the change:2023/12/29 2.Name of legal person: OBI Pharma Inc. 3.Name of the previous position holder: Chen-En Tsai 4.Resume of the previous …
The Company’s Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board
1.Date of the board of directors resolution or date of occurrence of the change:2023/12/29 2.Position (Please enter chairperson or president/general manager): Chairperson 3.Name of the …